<article>
 <front>
  <article-meta>
   <article-id>
    http://dx.doi.org/10.1016/j.jmb.2006.11.013
   </article-id>
  </article-meta>
  <title-group>
   <article-title>
    Solution Structure of a Hck SH3 Domain Ligand Complex Reveals Novel Interaction Modes
   </article-title>
  </title-group>
 </front>
 <body>
  <sec>
  </sec>
  <sec>
   <title>
    Abbreviations used
   </title>
   <ul>
    <li>
     <span>
      Hck
     </span>
     ,
     <span>
      hematopoietic cell kinase
     </span>
     ;
    </li>
    <li>
     <span>
      SH3
     </span>
     ,
     <span>
      Src homology 3
     </span>
     ;
    </li>
    <li>
     <span>
      SH2
     </span>
     ,
     <span>
      Src homology 2
     </span>
     ;
    </li>
    <li>
     <span>
      HckSH3
     </span>
     ,
     <span>
      Hck SH3 domain
     </span>
     ;
    </li>
    <li>
     <span>
      Fyn
     </span>
     ,
     <span>
      Fgr/Yes-related kinase
     </span>
     ;
    </li>
    <li>
     <span>
      Abl
     </span>
     ,
     <span>
      Abelson tyrosine kinase
     </span>
     ;
    </li>
    <li>
     <span>
      Src
     </span>
     ,
     <span>
      Rous sarcoma viral oncogene homolog
     </span>
     ;
    </li>
    <li>
     <span>
      Nef
     </span>
     ,
     <span>
      negative factor
     </span>
     ;
    </li>
    <li>
     <span>
      ADAM
     </span>
     ,
     <span>
      a disintegrin and metalloprotease
     </span>
     ;
    </li>
    <li>
     <span>
      PPII
     </span>
     ,
     <span>
      polyprolin helix type II
     </span>
     ;
    </li>
    <li>
     <span>
      HSQC
     </span>
     ,
     <span>
      heteronuclear single quantum coherence
     </span>
     ;
    </li>
    <li>
     <span>
      COSY
     </span>
     ,
     <span>
      correlated spectroscopy
     </span>
     ;
    </li>
    <li>
     <span>
      TOCSY
     </span>
     ,
     <span>
      total correlated spectroscopy
     </span>
     ;
    </li>
    <li>
     <span>
      NOE
     </span>
     ,
     <span>
      nuclear Overhauser enhancement
     </span>
     ;
    </li>
    <li>
     <span>
      NOESY
     </span>
     ,
     <span>
      NOE spectroscopy
     </span>
     ;
    </li>
    <li>
     <em>
      K
     </em>
     ,
     <span>
      dissociation constant
     </span>
     ;
    </li>
    <li>
     <span>
      ppm
     </span>
     ,
     <span>
      parts per million
     </span>
     ;
    </li>
    <li>
     <span>
      PDB
     </span>
     ,
     <span>
      Protein Data Bank
     </span>
     ;
    </li>
    <li>
     <span>
      BMRB
     </span>
     ,
     <span>
      Biological Magnetic Resonance Bank
     </span>
    </li>
   </ul>
  </sec>
  <sec>
   <title>
    Keywords
   </title>
   <ul>
    <li>
     <span>
      human Hck
     </span>
     ;
    </li>
    <li>
     <span>
      SH3-ligand interaction
     </span>
     ;
    </li>
    <li>
     <span>
      NMR
     </span>
     ;
    </li>
    <li>
     <span>
      complex structure
     </span>
    </li>
   </ul>
  </sec>
  <sec>
   <title>
    Introduction
   </title>
   <p>
    The hematopoietic cell kinase (p60
    <sup>
     hck
    </sup>
    /Hck) is a 60 kDa Src-related cytoplasmic protein tyrosine kinase expressed primarily in hematopoietic cells of myeloid and B-lymphoid origin.
    <sup>
     <a>
      1.
     </a>
     and
     <a>
      2.
     </a>
    </sup>
    Hck has been shown to be involved in myeloid cell growth, differentiation, and function. It has been identified as a signaling component of numerous receptor pathways including FcγR
    <a>
     <sup>
      3
     </sup>
    </a>
    (FcγRI,
    <a>
     <sup>
      4
     </sup>
    </a>
    FcγRII
    <a>
     <sup>
      5
     </sup>
    </a>
    ), Integrins
    <sup>
     <a>
      6.
     </a>
     and
     <a>
      7.
     </a>
    </sup>
    and Cytokine-mediated signal transduction (IL-2,
    <a>
     <sup>
      8
     </sup>
    </a>
    IL-3,
    <a>
     <sup>
      9
     </sup>
    </a>
    LIF/IL-6
    <a>
     <sup>
      10
     </sup>
    </a>
    , GM-CSF
    <a>
     <sup>
      11
     </sup>
    </a>
    ). Hck is involved in cytoskeletal reorganization,
    <sup>
     <a>
      12.
     </a>
     ,
     <a>
      13.
     </a>
     and
     <a>
      14.
     </a>
    </sup>
    apoptosis,
    <sup>
     <a>
      15.
     </a>
     and
     <a>
      16.
     </a>
    </sup>
    gene transcription,
    <a>
     <sup>
      17
     </sup>
    </a>
    regulation of K
    <sup>
     +
    </sup>
    -channels
    <a>
     <sup>
      18
     </sup>
    </a>
    as well as phagocytosis and degranulation.
    <sup>
     <a>
      19.
     </a>
     ,
     <a>
      20.
     </a>
     ,
     <a>
      21.
     </a>
     and
     <a>
      22.
     </a>
    </sup>
    It plays an important role in Bcr/Abl-induced leukemia
    <a>
     <sup>
      23
     </sup>
    </a>
    and in HIV disease. It binds to HIV-1 Nef
    <a>
     <sup>
      24
     </sup>
    </a>
    resulting in an increase of Hck kinase activity
    <em>
     in vitro
    </em>
    <a>
     <sup>
      25
     </sup>
    </a>
    and
    <em>
     in vivo
    </em>
    .
    <a>
     <sup>
      26
     </sup>
    </a>
    It also binds to HIV-1 Vif, which counteracts cellular activities that would otherwise limit HIV-1 replication by suppressing kinase activity.
    <a>
     <sup>
      27
     </sup>
    </a>
   </p>
   <p>
    According to the UniProtKB/Swiss-Prot family/domain classification, the human Src-type protein-tyrosine kinase family includes at least ten more members (Blk, Brk, Fgr, Frk, Fyn, Lck, Lyn, Src, Srm, Yes) in addition to Hck. They all consist of four consecutive domains, an amino-terminal “unique“ domain, an SH3 and an SH2 domain, which is separated by a short SH2-kinase linker region from the catalytic kinase domain that has a short carboxy-terminal regulatory tail. Three-dimensional structures are known for SH3, SH2 and kinase domains of Hck,
    <sup>
     <a>
      28.
     </a>
     ,
     <a>
      29.
     </a>
     ,
     <a>
      30.
     </a>
     and
     <a>
      31.
     </a>
    </sup>
    as well as for various other tyrosine kinases.
   </p>
   <p>
    The Src homology 3 (SH3) domain, which binds left-handed poly-proline type II (PPII) helices, is known to affect the localization of the protein
    <a>
     <sup>
      32
     </sup>
    </a>
    and recruit possible target proteins to the catalytic domain.
    <sup>
     <a>
      33.
     </a>
     and
     <a>
      34.
     </a>
    </sup>
    The SH3 domain negatively regulates kinase activity,
    <sup>
     <a>
      35.
     </a>
     and
     <a>
      36.
     </a>
    </sup>
    and mutations in the domain frequently result in constitutively active kinases.
    <sup>
     <a>
      37.
     </a>
     and
     <a>
      38.
     </a>
    </sup>
    HIV-1 Nef, on the other hand, stimulates the kinase activity by binding to the SH3 domain.
   </p>
   <p>
    The regulatory functions of the highly conserved SH2 and SH3 domains result from intramolecular interactions shown in the crystal structures of inactive Src and Hck.
    <sup>
     <a>
      39.
     </a>
     and
     <a>
      28.
     </a>
    </sup>
    Intramolecular binding of a phosphorylated tyrosine residue at the carboxy-terminal tail to the SH2 domain rearranges the SH2-kinase linker region, which then binds
    <em>
     via
    </em>
    its PPII helix to the SH3 domain. This interaction results in an intramolecular structural rearrangement at the active site of the kinase domain, which becomes inaccessible for substrates and the kinase activity is inhibited.
   </p>
   <p>
    Recently, we have identified an artificial peptide (<span id="" source="intactdb" intactdbid="17141806" annotator="elias" UNIPROT="7149158" type="participant">PD1</span>) to be a high affinity <span id="" source="intactdb" intactdbid="17141806" annotator="elias" UNIPROT="P08631" type="participant">HckSH3</span> ligand (
    <em>
     K
    </em>
    <sub>
     D
    </sub>
    = <span id="" source="intactdb" intactdbid="17141806" annotator="elias" type="value">0.2</span><span id="" source="intactdb" intactdbid="17141806" annotator="elias" type="unit">μM</span>) from screening a phage displayed peptide library against the closely related lymphocyte specific kinase (Lck) SH3 domain.
    <a>
     <sup>
      40
     </sup>
    </a>
    Compared to typical class I ligands, the PD1 amino acid sequence shows some unusual features. A basic residue is found at position P
    <sub>
     −4
    </sub>
    and not at the typical anchor position P
    <sub>
     −3
    </sub>
    , where it contains a hydrophobic tyrosine instead. We determined the solution structure of the HckSH3:PD1 complex to elucidate the structural basis of the high affinity of PD1 to HckSH3.
   </p>
  </sec>
  <sec>
   <title>
    Results
   </title>
   <title>
    Determination of the dissociation constant between PD1 and HckSH3 and mapping of the PD1 binding site
   </title>
   <p>
    To obtain the dissociation constant (
    <em>
     K
    </em>
    <sub>
     D
    </sub>
    ) of the phage display selected peptide <span id="7149249" source="intactdb" intactdbid="17141806" annotator="elias" UNIPROT="7149158" type="participant">PD1</span> to <span id="7149249" source="intactdb" intactdbid="17141806" annotator="elias" UNIPROT="P08631" type="participant">HckSH3</span>, fluorescence titrations were carried out.
    <sup>
     <a>
      41.
     </a>
     and
     <a>
      42.
     </a>
    </sup>
    The resulting
    <em>
     K
    </em>
    <sub>
     D
    </sub>
    value was determined to be <span id="7149249" source="intactdb" intactdbid="17141806" annotator="elias" type="value">0.23</span><span id="7149249" source="intactdb" intactdbid="17141806" annotator="elias" type="unit">μM</span>(
    <a>
     Table 1
    </a>
    ).
   </p>
  </sec>
 </body>
</article>
